Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 5/20 | 0.34 |
| ▸ | AKT1 | P31749 | 8/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | RAC1 | P63000 | 1/20 | 0.32 |
| ▸ | GPR183 | P32249 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17828197 | 0.90 | ALDH1A1 (0.39) | PIK3CA | |
| SCHEMBL17820942 | 0.89 | PIK3C3 (0.36) | PIK3C3AKT1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL17820057 | 0.87 | PIK3C3 (0.42) | PIK3C3HRH3ATMEPHX2 | |
| SCHEMBL17820146 | 0.84 | PIK3C3 (0.40) | PIK3C3ATM | |
| SCHEMBL17820263 | 0.82 | PIK3C3 (0.41) | PIK3C3ATM | |
| SCHEMBL17819804 | 0.82 | ATM (0.39) | PIK3C3HRH3ATMCYP3A4 | |
| SCHEMBL17819824 | 0.81 | PIK3C3 (0.41) | PIK3C3PIK3CDPIK3CBATM | |
| SCHEMBL17819767 | 0.80 | PIK3C3 (0.43) | PIK3C3HRH3ATM | |
| SCHEMBL17820618 | 0.80 | PIK3C3 (0.43) | PIK3C3ATM | |
| SCHEMBL17820553 | 0.78 | PIK3C3 (0.40) | PIK3C3ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3042900-B1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORP (JP) | 2020-09-23 | — | — | EP | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | PIK3C3 3047/4885AKT1 1185/4885PIK3CD 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.